2. 筋萎縮性側索硬化症 Amyotrophic lateral sclerosis Clinical trials / Disease details
臨床試験数 : 624 / 薬物数 : 611 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04322149 (ClinicalTrials.gov) | October 16, 2020 | 20/3/2020 | Multiple Doses of AT-1501-A201 in Adults With ALS | A Phase 2a Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Multiple Doses of AT-1501 in Adults With ALS | Amyotrophic Lateral Sclerosis | Drug: AT-1501 | Anelixis Therapeutics, LLC | NULL | Active, not recruiting | 18 Years | N/A | All | 54 | Phase 2 | United States;Canada |